genprowebdirectory
GEN Edge
News
Insights
Trends for 2021
Trends for 2020
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Get GEN Edge
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
GEN Edge
Drug Discovery
Delivering on a Promise: The Present and Future of Targeted Protein…
Gene Therapy
OXGENE Eyes Further Growth in Cell and Gene Therapy Services after…
Coronavirus
Breathe In: Theravance Reports Positive Phase II Data for JAK Inhibitor
Cancer
The Life Oncolytic, with Stephen Russell
Synthetic Biology
Flush with Cash, Foresite Aims to Live Up to Its Name
News
Antibodies
CRISPR-Cas9 Screening Enables Phenotypic Development of Antibody Drugs
Bioprocessing
FUJIFILM Diosynth Biotechnologies Expands Cell Culture Capacity in Denmark
Bioprocessing
Pharmaron Acquires Bioprocessing Site from AbbVie
Natural Products
Catnip’s Effectiveness as a Natural Mosquito Repellent Linked to Irritant Receptor…
Cancer
Collagen Plays Protective Role during Pancreatic Cancer Development
Insights
All
Trends for 2021
Trends for 2020
Bioprocessing
Harvesting Plastic from Plants
Infectious Diseases
SARS-CoV-2 Under Surveillance
Cancer
Immune Cell Profiles Reveal Cancer’s Leading Indicators
Translational Medicine
Animal Models Offer Improved Translatability
A-Lists
A-Lists
Top 7 Best Selling COVID-19 Vaccines and Drugs of 2020
January 2021 Vol. 41 No. 1
Seven Biopharma Trends to Watch in 2021
A-Lists
Top 15 Best-Selling Drugs Launched in 2020
A-Lists
Top 50 NIH-Funded Institutions of 2020
July 2020 Vol. 40 No. 7
Top 10 Earners among Women Biopharma Executives
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Antibodies
CRISPR-Cas9 Screening Enables Phenotypic Development of Antibody Drugs
Bioprocessing
FUJIFILM Diosynth Biotechnologies Expands Cell Culture Capacity in Denmark
Bioprocessing
Pharmaron Acquires Bioprocessing Site from AbbVie
Cancer
Collagen Plays Protective Role during Pancreatic Cancer Development
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Home
Neurological Disorders
ALS
ALS
Most popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
ALS
Sanofi, Denali Launch $1B+ Alliance to Develop RIPK1 Inhibitors for Neurological, Inflammatory Diseases
ALS
Amyloids Shown to Also Play Beneficial Role in Developing Healthy Muscle Tissue
ALS
Five Life Sciences Researchers Win Breakthrough Prizes Totaling $15M
ALS
Studying Changing Neuron Size May Lead to New Therapies for Motor Neuron Disease
ALS
Size Matters: Study Reveals “Brain Reserve” Genes
ALS
Hardening of the RNA Condensates May Solidify Neurodegeneration
ALS
Novel Research Model Offers Hope to ALS and MS Patients
ALS
Biogen, Ionis Launch $1B+ Expanded Neuro Drug Partnership, following Spinraza Success
ALS
Neuraltus Weighs Future of Lead Candidate NP001 after Failure in Phase...
ALS
Flex Pharma Axes 60% of Workforce, Explores Sale after Halting Phase...
ALS
Sangamo, Pfizer Partner on Gene Therapy for ALS, FTLD
ALS
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders
ALS
Proteomics Finding May Lead to Therapy Targeted at Cellular Pathway Linked...
ALS
CRISPR Human Knockout Screens Identify New Target for ALS
ALS
CRISPR Screen Identifies Genetic Modifiers of ALS
1
2
Page 1 of 2
Scroll Up
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
/* The alert message box */ .alert { padding: 20px; background-color: #ff9800; /* Red */ color: white; margin-bottom: 15px; } /* The close button */ .closebtn { margin-left: 15px; color: white; font-weight: bold; float: right; font-size: 22px; line-height: 20px; cursor: pointer; transition: 0.3s; } /* When moving the mouse over the close button */ .closebtn:hover { color: black; } .td_module_flex_2 .entry-title { font-size: 17px; line-height: 20px; }
![Flex Pharma cites unspecified “oral tolerability concerns” in halting Phase II trials of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT). [© whitehoune / Fotolia]](https://www.genengnews.com/wp-content/uploads/2018/08/170123090806_1_900x6009916143062-324x160.jpg "Flex Pharma Axes 60% of Workforce, Explores Sale after Halting Phase II Trials in ALS, CMT")
